secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001739410-25-000052
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio discontinues RLYB212 for FNAIT after Phase 2 PK misses efficacy targets
--------------------------------------------------------------------------------

- Phase 2 PK results: RLYB212 concentrations near/ below assay LLoQ, missing minimum target of 3 ng/mL and predicted 6-10 ng/mL.
- No further enrollment; safety follow-up of sentinel participant continues; dose adjustment not feasible.
- RLYB116 confirmatory PK/PD study to initiate Q2 2025 with data from Cohorts 1 and 2 in 3Q/4Q 2025.
- REV102 (ENPP1 inhibitor, JV with Recursion) in IND-enabling studies; Phase 1 expected 2026; preclinical data 2H 2025.
- RLYB332 (long-acting matriptase-2 antibody) preclinical development ongoing for iron overload diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000052/0001739410-25-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941025000052/rlyb-20250408.htm
  HTML page:      https://secwatch.observer/filing/0001739410-25-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer